Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow Mononuclear Cell Transplantation for Cerebral Embolism
NCT01028794Phase 2Completed
- Sponsor
- National Cerebral and Cardiovascular Center
- Start
- May 2008
- Primary completion
- Jul 2013
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous bone marrow-derived mononuclear cell in cerebral embolism (2 arms), sponsored by National Cerebral and Cardiovascular Center. Primary endpoints: Improvement of National Institute of Health Stroke Scale at 30 days and Frequency of change for the worse in NIHSS at 30 days. Started May 2008; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
cerebral embolism
Beyond the preview
Go deeper on NCT01028794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01028794.